Mizuho lowered the firm’s price target on MannKind (MNKD) to $8 from $10 and keeps an Outperform rating on the shares. The firm adjusted estimates and price targets for several names in its medical devices and diagnostics coverage ahead of Q1 earnings from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind price target lowered to $6 from $7 at Truist
- Theravance Biopharma price target raised to $17 from $14 at B. Riley
- MannKind price target lowered to $8 from $10 at Wedbush
- Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
- MannKind price target lowered to $7 from $8 at Wells Fargo